From: Predictors of pulmonary embolism in hospitalized patients with COVID-19
Characteristics | Positive chest CTA consistent with a PE | Negative chest CTA ruling out a PE | Total | P-value |
---|---|---|---|---|
Demographics | Â | Â | Â | Â |
Age (yr), median (IQR) Males Females BMI (kg/m2), median (IQR) | 59 (49-71) 40 (61) 26 (39) 28.6 (24.6-35.0) | 64.5 (52.8-71) 48 (52) 44 (48) 27.6 (23.4-33.2) | 62.5 (49.3-71.0) 88 (56) 70 (44) 28 (23.7-33.9) | 0.40 0.37 0.32 |
Race | Â | Â | Â | Â |
Black or African American Hispanic White Asian Others | 18 (27) 15 (23) 22 (33) 0 (0) 11 (17) | 24 (26) 22 (24) 12 (13) 9 (10) 25 (27) | 42 (27) 37 (23) 34 (22) 9 (6) 36 (23) | 0.002 |
Comorbidities | Â | Â | Â | Â |
Hypertension Diabetes Hyperlipidemia Active malignancy COPD/asthma Coronary artery disease Congestive heart failure Atrial fibrillation Chronic kidney disease Chronic liver disease Cerebrovascular accident Myocardial infarction Autoimmune disease Previous gastrointestinal bleed Prior DVT/PE Oral contraceptive pill use | 25 (38) 17 (26) 19 (29) 6 (9) 6 (9) 8 (12) 2 (3) 3 (5) 4 (6) 1 (2) 5 (8) 1 (2) 7 (11) 0 (0) 7 (11) 0 (0) | 50 (54) 24 (26) 31 (34) 16 (17) 22 (24) 17 (19) 9 (10) 8 (9) 10 (11) 4 (4) 9 (10) 6 (7) 8 (9) 4 (4) 12 (13) 1 (1) | 75 (48) 41 (26) 50 (32) 22 (14) 28 (18) 25 (16) 11 (7) 11 (7) 14 (9) 5 (3) 14 (9) 7 (6) 15 (10) 4 (3) 19 (12) 1 (1) | 0.05 1.00 0.63 0.21 0.03 0.39 0.18 0.36 0.40 0.40 0.84 0.24 0.90 0.14 0.83 1.00 |
Smoking | Â | Â | Â | Â |
No | 46 (70) | 62 (67) | 108 (68) | 0.89 |
Active/prior | 20 (30) | 30 (33) | 50 (32) | Â |
Family history of DVT/PE | 2 (3) | 0 (0) | 2 (1) | 0.17 |
History suggestive of hyper-coagulable state | 2 (3) | 7 (8) | 9 (6) | 0.31 |
Recent surgery / immobilization | 8 (12) | 4 (4) | 12 (8) | 0.12 |
Chronic home anticoagulation | Â | Â | Â | Â |
None Lovenox/DOAC/coumadin Antiplatelet DAPT | 63 (96) 3 (5) 9 (14) 1 (2) | 83 (90) 9 (10) 20 (22) 3 (3) | 146 (92) 12 (8) 29 (18) 4 (3) | 0.36 0.28 0.64 |
Prophylactic anticoagulation | Â | Â | Â | 0.046 |
Prophylactic LMWH Therapeutic LMWH UFH DOAC | 34 (37) 4 (4) 19 (21) 8 (9) | 14 (21) 6 (9) 12 (18) 4 (6) | 48 (30) 10 (60) 30 (20) 12 (76) | Â |
Length of stay (mean days) | 14.6 | 13.7 | Â | 0.158 |
Severity of parenchymal lung disease | Â | Â | Â | Â |
None Mild Moderate Severe | 10 27 20 9 | 12 30 30 20 | Â | 0.817 0.394 |